Abstract
The use of antipsychotic medications presents a trade-off for the treating physician. On the one hand, there is enough literature regarding the efficacy of these medications to support their judicial use, while on the other, chronic and at time impairing side effects are troubling to both physicians and the patients. Extrapyramidal side effects are the hallmark of first-generation antipsychotics, while metabolic side effects including weight gain, diabetes mellitus, and lipid abnormalities are more common with second-generation antipsychotics. This article presents a concise overview of the current literature on antipsychotic-related side effects and treatment options.
Keywords: Mental health, children, and adolescents, psychopharmacology, antipsychotics, side effects, psychotropics.
Current Psychopharmacology
Title:Management of Adverse Effects from Atypical Antipsychotics
Volume: 7
Author(s): Ahsan Nazeer*Joseph L. Calles
Affiliation:
- Department of Psychiatry, Sidra Medical and Research Center. C2M 224, 2nd Mezzanine, OPC, PO Box 26999, Al Luqta Street, Education City North Campus, Qatar Foundation, Doha,Qatar
Keywords: Mental health, children, and adolescents, psychopharmacology, antipsychotics, side effects, psychotropics.
Abstract: The use of antipsychotic medications presents a trade-off for the treating physician. On the one hand, there is enough literature regarding the efficacy of these medications to support their judicial use, while on the other, chronic and at time impairing side effects are troubling to both physicians and the patients. Extrapyramidal side effects are the hallmark of first-generation antipsychotics, while metabolic side effects including weight gain, diabetes mellitus, and lipid abnormalities are more common with second-generation antipsychotics. This article presents a concise overview of the current literature on antipsychotic-related side effects and treatment options.
Export Options
About this article
Cite this article as:
Nazeer Ahsan *, Calles L. Joseph , Management of Adverse Effects from Atypical Antipsychotics, Current Psychopharmacology 2018; 7 (1) . https://dx.doi.org/10.2174/2211556007666180220162945
DOI https://dx.doi.org/10.2174/2211556007666180220162945 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Editorial (Thematic Issue: Global Trends in Nanotechnological Approaches for Various Health Issues – Volume II)
Current Drug Metabolism Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design α7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia
Current Medicinal Chemistry - Central Nervous System Agents Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Editorial (Thematic Issue: Current Topics in Pharmacogenomics)
Recent Patents on Biotechnology Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology The Potential for Dietary Modification of Islet β-Cell Homeostasis in Autoimmune Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Anodic Voltammetric Behavior and Determination of Rosiglitazone in Pharmaceutical Dosage Forms and Biological Fluids on Solid Electrode
Combinatorial Chemistry & High Throughput Screening Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Schiff Bases of Istain: Antiglycation Activity
Letters in Drug Design & Discovery Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research